Actively Recruiting

Age: 18Years - 45Years
FEMALE
Healthy Volunteers
ID07620067

Gonadotropin-Releasing Hormone Agonist as a Single Luteal Support What is Its Mechanism of Action?

Led by Heli Alexandroni · Updated on 2026-06-02

150

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are investigating the use of GnRH agonists as the sole luteal phase support during IVF treatment for women undergoing a GnRH antagonist protocol with fresh embryo transfer. The study aims to understand how GnRH agonists work to improve pregnancy outcomes and to identify factors that may predict treatment success or failure. This observational study involves women aged 18 to 45 undergoing their first to third IVF cycle for various infertility causes. Participants will follow a controlled ovarian stimulation protocol with gonadotropins and daily GnRH antagonist injections until ovulation induction. Ovulation triggering is done with hCG, GnRH agonist, or a combination depending on the risk of ovarian hyperstimulation syndrome. After egg retrieval and fertilization via IVF or ICSI, embryos are cultured and transferred. Luteal phase support is provided either by intranasal GnRH agonist spray (200 mcg Nafarelin twice daily for two weeks) or vaginal progesterone, with progesterone continuing in pregnancy up to 8-10 weeks. Throughout the study, blood and follicular fluid samples will be collected at six time points to measure hormonal, inflammatory, and angiogenic markers. Researchers will monitor demographic and clinical data, IVF cycle parameters, embryo quality, and pregnancy outcomes such as positive pregnancy rate, miscarriage, live birth, and complications like OHSS. The study lasts at least two weeks after embryo transfer for primary outcomes, with further follow-up for pregnancy progress.

CONDITIONS

Brief Title

GnRH for Luteal Support - Mechanism of Action

Who Can Participate

Age: 18Years - 45Years
FEMALE
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Women aged 18 to 45 years
  • Undergoing IVF treatment due to ovulation disorder, mechanical factor, primary ovarian insufficiency, or male infertility
  • At their first to third IVF treatment cycle
  • Undergoing fresh embryo transfer
Not Eligible

You will not qualify if you...

  • History of repeated implantation failure (more than 3 cycles of good quality embryo transfer without implantation)
  • Moderate to severe endometriosis
  • Presence of hydrosalpinx
  • Fibroid uterus
  • Body mass index (BMI) less than 19 or greater than 35
  • Hypogonadotropic hypogonadism
  • Use of pre-implantation genetic testing (PGT) of embryos
  • Use of surgical techniques for sperm retrieval
  • Preference for long GnRH-agonist protocol
  • Current rhinitis or nasal congestion

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Monitoring

Duration - Up to 1 month

Participants undergoing IVF treatment are observed during ovarian stimulation and egg retrieval procedures, including blood sample collections and embryo evaluations.

Multiple visits including ovum pick-up day and day of embryo transfer

Treatment

Duration - 2 weeks for GnRH agonist; progesterone continued up to 8-10 weeks if pregnancy is positive

Participants receive luteal phase support with either intranasal GnRH agonist spray twice daily for two weeks or vaginal progesterone, continuing progesterone if pregnancy is confirmed.

Daily administration for 2 weeks with blood sample collections on specific days

Long-term Monitoring

Duration - Up to 10 weeks if pregnancy occurs

Participants are monitored after treatment to assess pregnancy outcomes and collect follow-up blood samples.

Blood sample collections at 12 and 14 days after embryo transfer

Trial Site Locations

Total: 1 location

1

Shaare Zedek Medical Center

Jerusalem, Israel, 9103102

Actively Recruiting

Loading map...

Research Team

H

Heli Alexandroni, MD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Similar Trials

Effectiveness and Safety of In Vitro Maturation With Fresh E...

Polycystic Ovary Syndrome (PCOS)

Actively Recruiting

1 location

Balancing Comfort and Success: Post-retrieval Ketorolac in F...

Infertility (IVF Patients)

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here